Osteoporosis Pipeline Summary

DelveInsight’s, “Osteoporosis - Pipeline Insight, 2026” report provides comprehensive insights about 38+ companies and 40+ pipeline drugs in Osteoporosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Osteoporosis: Understanding

Osteoporosis: Overview

Osteoporosis is a condition characterized by a decrease in the density of bone, decreasing its strength and resulting in fragile bones. Osteoporosis literally leads to the abnormally porous bone that is compressible, like a sponge. This disorder of the skeleton weakens the bone and results in frequent fractures (breaks) in the bones. Osteoporosis can be present without any symptoms for decades because osteoporosis doesn't cause symptoms until bone breaks (fractures). Key risk factors for osteoporosis include genetics, lack of exercise, lack of calcium and vitamin D, personal history of fracture as an adult, cigarette smoking, excessive alcohol consumption, history of rheumatoid arthritis, low body weight, and family history of osteoporosis. The long-term use of corticosteroids (such as prednisone, cortisone, and prednisolone) can lead to osteoporosis

Osteoporosis is often termed a "silent disease" because it typically does not present noticeable symptoms until significant bone loss has occurred. Early signs may include subtle changes such as receding gums, weakened grip strength, and minor back or neck pain. As the condition progresses, more pronounced symptoms emerge, including a noticeable loss of height, stooped posture, and an increased frequency of fractures, particularly in the wrist, hip, and spine, even from minor falls or stress. These fractures can lead to severe pain and complications, highlighting the importance of early detection and management of osteoporosis to prevent debilitating injuries.

The pathophysiology involves an imbalance between bone resorption by osteoclasts and bone formation by osteoblasts, often exacerbated by factors such as aging, hormonal changes particularly estrogen deficiency in postmenopausal women—and various medical conditions. The disease is multifactorial, influenced by genetic predisposition, nutritional factors (such as calcium and vitamin D deficiency), lifestyle choices (like physical inactivity and smoking), and certain medications. As a result, bones become porous and weak, making individuals susceptible to fractures even from minor falls or injuries, with common sites including the hip, wrist, and spine

The diagnosis of osteoporosis can be suggested by X-rays and confirmed by tests to measure bone density. The National Osteoporosis Foundation, the American Medical Association, and other major medical organizations recommend a dual-energy X-ray absorptiometry scan (DXA, formerly known as DEXA) be used for the diagnosis of osteoporosis. DXA typically measures bone density in the hip, the spine, and the forearm.

The treatment of osteoporosis aims to prevent bone fractures by reducing bone loss or ideally increasing bone density and strength. Effective measures include lifestyle changes such as quitting smoking, limiting alcohol, exercising regularly, and maintaining a balanced diet with adequate calcium and vitamin D.

"Osteoporosis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteoporosis pipeline landscape is provided which includes the disease overview and Osteoporosis treatment guidelines. The assessment part of the report embraces, in depth Osteoporosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteoporosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Osteoporosis R&D. The therapies under development are focused on novel approaches to treat/improve Osteoporosis.

Osteoporosis Emerging Drugs Chapters

This segment of the Osteoporosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Osteoporosis Emerging Drugs

• EB613: Entera Bio

EB613 is an investigational once-daily oral anabolic therapy containing PTH(1-34) (teriparatide) for the treatment of postmenopausal osteoporosis. It is designed to offer a convenient oral alternative to injectable anabolic therapies, potentially improving patient acceptance and adherence. EB613 has demonstrated positive Phase II results, including improvements in bone mineral density at key skeletal sites, and Entera is preparing to advance the therapy into Phase III development in late 2026. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Osteoporosis.

• AGA2118: Angitia Biopharmaceuticals

AGA2118 is a bispecific antibody that targets sclerostin and DKK1 and is in clinical development for the treatment of osteoporosis. Sclerostin and DKK1 are two critical, negative regulators of WNT signaling in osteoblasts and of bone metabolism. By targeting both proteins, AGA2118 is thought to prevent compensatory increase of either agent, aiming to improve the magnitude of bone mineral density gains in osteoporotic patients. Angitia is developing AGA2118 in OLYMPUS (Osteoporosis Longitudinal multi-Year prograM to evaluate Postmenopausal women at risk for fractUreS), which is currently under investigation in the ARTEMIS Phase II trial (A Phase II Randomized Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS).

• HMM-910: Help Therapeutics

HMM-910 is a human umbilical cord-derived mesenchymal stem cell (MSC) therapy developed by HELP Therapeutics for the treatment of postmenopausal osteoporosis. The therapy is administered by intravenous infusion and is being evaluated in postmenopausal women with osteoporosis who are at high risk of fracture. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Osteoporosis.

• RAB202: Zhongshan Laibo Ruichen Biomedicine

RAB202 is a first-in-class (FIC) peptide candidate being developed by Zhongshan Laibo Ruichen Biomedicine for once-weekly treatment of osteoporosis. Preclinical studies showed that RAB202 increased trabecular bone density at a level comparable to daily injected PTH. In vitro, RAB202 was shown to bind with high affinity to bone-derived progenitor cells (OPCs), promoting their survival, proliferation, and differentiation into osteoblasts, while maintaining mesenchymal stem cell activity and accelerating osteoblast maturation and mineralized nodule formation. In an ovariectomized (OVX) mouse model, weekly administration of RAB202 significantly increased the bone-formation marker BALP, decreased the bone-resorption marker CTX-1, and improved trabecular microstructure and spinal biomechanical properties. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Osteoporosis.

Further product details are provided in the report……..

Osteoporosis: Therapeutic Assessment

This segment of the report provides insights about the different Osteoporosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Osteoporosis

There are approx. 38+ key companies which are developing the therapies Osteoporosis. The companies which have their Osteoporosis drug candidates in the most advanced stage, i.e. Phase II include, Entera Bio, and others.

• Phases

DelveInsight’s report covers around 40+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Osteoporosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Osteoporosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteoporosis drugs.

Osteoporosis Report Insights

• Osteoporosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Osteoporosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Osteoporosis drugs?
• How many Osteoporosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteoporosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Osteoporosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Osteoporosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Entera Bio
• Angitia Biopharmaceuticals
• Help Therapeutics
• Zhongshan Laibo Ruichen Biomedicine
• ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
• Transcenta Holding Limited
• GlycoNex Inc.

Key Products

• EB613
• HMM-910
• AGA2118
• RAB202
• RAB-004
• RAB-007
• RAB-010
• IMM721/IMC-004
• TST973
• TST901
• SPD8